Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 1 to 20 of 155

2.

Greater seasonal cycling of 25-hydroxyvitamin D is associated with increased parathyroid hormone and bone resorption.

Darling AL, Hart KH, Gibbs MA, Gossiel F, Kantermann T, Horton K, Johnsen S, Berry JL, Skene DJ, Eastell R, Vieth R, Lanham-New SA.

Osteoporos Int. 2014 Mar;25(3):933-41. doi: 10.1007/s00198-013-2493-4. Epub 2013 Aug 28.

PMID:
23982802
[PubMed - in process]
3.

Effect of vitamin D replacement on hip structural geometry in adolescents: a randomized controlled trial.

Al-Shaar L, Nabulsi M, Maalouf J, El-Rassi R, Vieth R, Beck TJ, El-Hajj Fuleihan G.

Bone. 2013 Oct;56(2):296-303. doi: 10.1016/j.bone.2013.06.020. Epub 2013 Jun 28.

PMID:
23810841
[PubMed - indexed for MEDLINE]
4.

Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue.

Giangreco AA, Vaishnav A, Wagner D, Finelli A, Fleshner N, Van der Kwast T, Vieth R, Nonn L.

Cancer Prev Res (Phila). 2013 May;6(5):483-94. doi: 10.1158/1940-6207.CAPR-12-0253. Epub 2013 Mar 15.

PMID:
23503652
[PubMed - indexed for MEDLINE]
5.

Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.

Chow EC, Quach HP, Vieth R, Pang KS.

Am J Physiol Endocrinol Metab. 2013 May 1;304(9):E977-89. doi: 10.1152/ajpendo.00489.2012. Epub 2013 Mar 12.

PMID:
23482451
[PubMed - indexed for MEDLINE]
6.

Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients.

Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M, Laszlo S, Hersey K, Klotz L, Finelli A, Fleshner N, Vieth R.

J Clin Endocrinol Metab. 2013 Apr;98(4):1498-507. doi: 10.1210/jc.2012-4019. Epub 2013 Mar 5.

PMID:
23463655
[PubMed - indexed for MEDLINE]
7.

Prospective association of 25(OH)D with metabolic syndrome.

Kayaniyil S, Harris SB, Retnakaran R, Vieth R, Knight JA, Gerstein HC, Perkins BA, Zinman B, Hanley AJ.

Clin Endocrinol (Oxf). 2014 Apr;80(4):502-7. doi: 10.1111/cen.12190. Epub 2013 Apr 1.

PMID:
23452164
[PubMed - in process]
8.

The future of "vitamin D", i.e. 25-hydroxyvitamin D, testing.

Vieth R.

Clin Biochem. 2013 Feb;46(3):189. doi: 10.1016/j.clinbiochem.2012.12.018. No abstract available.

PMID:
23298561
[PubMed - indexed for MEDLINE]
9.

Longitudinal study of vitamin D metabolites after long bone fracture.

Briggs AD, Kuan V, Greiller CL, Maclaughlin BD, Ramachandran M, Harris T, Timms PM, Venton TR, Vieth R, Norman AW, Griffiths CJ, Martineau AR.

J Bone Miner Res. 2013 Jun;28(6):1301-7. doi: 10.1002/jbmr.1855.

PMID:
23281057
[PubMed - indexed for MEDLINE]
10.

Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.

Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1239-45. doi: 10.1016/j.ijrobp.2012.11.007. Epub 2012 Dec 19.

PMID:
23265571
[PubMed - indexed for MEDLINE]
11.

Solar ultraviolet-B radiation and vitamin D: a cross-sectional population-based study using data from the 2007 to 2009 Canadian Health Measures Survey.

Greenfield JA, Park PS, Farahani E, Malik S, Vieth R, McFarlane NA, Shepherd TG, Knight JA.

BMC Public Health. 2012 Aug 15;12:660. doi: 10.1186/1471-2458-12-660.

PMID:
22894564
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis.

Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S, Chope G, Hyppönen E, Berry J, Vieth R, Lanham-New S.

Am J Clin Nutr. 2012 Jun;95(6):1357-64. doi: 10.3945/ajcn.111.031070. Epub 2012 May 2. Review.

PMID:
22552031
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Implications for 25-hydroxyvitamin D testing of public health policies about the benefits and risks of vitamin D fortification and supplementation.

Vieth R.

Scand J Clin Lab Invest Suppl. 2012 Apr;243:144-53. doi: 10.3109/00365513.2012.682893.

PMID:
22536776
[PubMed - indexed for MEDLINE]
14.

Determination of 1,25-dihydroxyvitamin D concentrations in human colon tissues and matched serum samples.

Wagner D, Dias AG, Schnabl K, Van der Kwast T, Vieth R.

Anticancer Res. 2012 Jan;32(1):259-63.

PMID:
22213314
[PubMed - indexed for MEDLINE]
15.

Association between serum 25-hydroxyvitamin D in early pregnancy and risk of gestational diabetes mellitus.

Parlea L, Bromberg IL, Feig DS, Vieth R, Merman E, Lipscombe LL.

Diabet Med. 2012 Jul;29(7):e25-32. doi: 10.1111/j.1464-5491.2011.03550.x.

PMID:
22150870
[PubMed - indexed for MEDLINE]
16.

Prospective associations of vitamin D with β-cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study.

Kayaniyil S, Retnakaran R, Harris SB, Vieth R, Knight JA, Gerstein HC, Perkins BA, Zinman B, Hanley AJ.

Diabetes. 2011 Nov;60(11):2947-53. doi: 10.2337/db11-0465. Epub 2011 Sep 12.

PMID:
21911752
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Why the minimum desirable serum 25-hydroxyvitamin D level should be 75 nmol/L (30 ng/ml).

Vieth R.

Best Pract Res Clin Endocrinol Metab. 2011 Aug;25(4):681-91. doi: 10.1016/j.beem.2011.06.009.

PMID:
21872808
[PubMed - indexed for MEDLINE]
18.

Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis.

Kimball S, Vieth R, Dosch HM, Bar-Or A, Cheung R, Gagne D, O'Connor P, D'Souza C, Ursell M, Burton JM.

J Clin Endocrinol Metab. 2011 Sep;96(9):2826-34. doi: 10.1210/jc.2011-0325. Epub 2011 Jun 22.

PMID:
21697250
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial.

Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, Rieckmann P, Schluep M, Vieth R, Hostalek U, Ghazi-Visser L, Beelke M; SOLAR study group.

J Neurol Sci. 2011 Dec 15;311(1-2):44-9. doi: 10.1016/j.jns.2011.04.013. Epub 2011 May 28.

PMID:
21620416
[PubMed - indexed for MEDLINE]
20.

The ratio of serum 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) is predictive of 25-hydroxyvitamin D(3) response to vitamin D(3) supplementation.

Wagner D, Hanwell HE, Schnabl K, Yazdanpanah M, Kimball S, Fu L, Sidhom G, Rousseau D, Cole DE, Vieth R.

J Steroid Biochem Mol Biol. 2011 Sep;126(3-5):72-7. doi: 10.1016/j.jsbmb.2011.05.003. Epub 2011 May 13.

PMID:
21605672
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk